<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38574">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604264</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-0001</org_study_id>
    <nct_id>NCT02604264</nct_id>
  </id_info>
  <brief_title>Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap</brief_title>
  <official_title>Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pursuit Vascular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pursuit Vascular, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess positive blood cultures (PBCs) in hemodialysis central venous catheter (CVC)
      patients using two FDA cleared devices: ClearGuard HD end caps compared to conventional end
      caps.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of positive blood cultures per 100 patient-months</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3500</enrollment>
  <condition>End Stage Renal Disease (ESRD)</condition>
  <arm_group>
    <arm_group_label>ClearGuard HD end cap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard hemodialysis end cap</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClearGuard HD end cap</intervention_name>
    <description>The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub</description>
    <arm_group_label>ClearGuard HD end cap</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients dialyzing with a central venous catheter

        Exclusion Criteria:

          -  Known allergy to chlorhexidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Hymes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fresenius Medical Care North America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frenova Renal Research</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pursuitvascular.com</url>
    <description>Pursuit Vascular website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 16, 2015</lastchanged_date>
  <firstreceived_date>November 11, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
